Search

Your search keyword '"Jett, James R."' showing total 243 results
Start Over Author "Jett, James R." Search Limiters Academic (Peer-Reviewed) Journals
243 results on '"Jett, James R."'

1. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Author

Hirsch, Fred R., Kerr, Keith M., Bunn, Paul A., Jr., Kim, Edward S., Obasaju, Coleman, Pérol, Maurice, Bonomi, Philip, Bradley, Jeffrey D., Gandara, David, Jett, James R., Langer, Corey J., Natale, Ronald B., Novello, Silvia, Paz-Ares, Luis, Ramalingam, Suresh S., Reck, Martin, Reynolds, Craig H., Smit, Egbert F., Socinski, Mark A., Spigel, David R., Stinchcombe, Thomas E., Vansteenkiste, Johan F., Wakelee, Heather, and Thatcher, Nick

Published
2018
Full Text
View/download PDF

2. Scientific Advances in Thoracic Oncology 2016

Author

Soo, Ross A., Stone, Emily C.A., Cummings, K. Michael, Jett, James R., Field, John K., Groen, Harry J.M., Mulshine, James L., Yatabe, Yasushi, Bubendorf, Lukas, Dacic, Sanja, Rami-Porta, Ramon, Detterbeck, Frank C., Lim, Eric, Asamura, Hisao, Donington, Jessica, Wakelee, Heather A., Wu, Yi-Long, Higgins, Kristin, Senan, Suresh, Solomon, Benjamin, Kim, Dong-Wan, Johnson, Melissa, Yang, James C.H., Sequist, Lecia V., Shaw, Alice T., Ahn, Myung-Ju, Costa, Daniel B., Patel, Jyoti D., Horn, Leora, Gettinger, Scott, Peters, Solange, Wynes, Murry W., Faivre-Finn, Corinne, Rudin, Charles M., Tsao, Anne, Baas, Paul, Kelly, Ronan J., Leighl, Natasha B., Scagliotti, Giorgio V., Gandara, David R., Hirsch, Fred R., and Spigel, David R.

Published
2017
Full Text
View/download PDF

14. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)

Author

Johnson, Elizabeth A., Marks, Randolph S., Mandrekar, Sumithra J., Hillman, Shauna L., Hauge, Mark D., Bauman, Mitchel D., Wos, Edward J., Moore, Dennis F., Kugler, John W., Windschitl, Harold E., Graham, David L., Bernath, Albert M., Jr., Fitch, Tom R., Soori, Gamini S., Jett, James R., Adjei, Alex A., and Perez, Edith A.

Published
2008
Full Text
View/download PDF

17. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of position emission tomography in diagnosis

Author

Patel, Rajesh R., Subramaniam, Rathan M., Mandrekar, Jaywant N., Hammack, Julie E., Lowe, Val J., and Jett, James R.

Subjects
Nervous system diseases -- Prognosis, Nervous system diseases -- Diagnosis, PET imaging -- Usage
Abstract

OBJECTIVE: To determine the value of positron emission tomography (PET) in diagnosing occult malignancies in pateints with paraneoplatic neurologic syndromes (PNSs) at Mayo Clinic's site in Rochester, MN. PATIENTS AND [...]

Published
2008

18. Computed tomography screening and lung cancer outcomes

Author

Bach, Peter B., Jett, James R., Pastorino, Ugo, Tockman, Melvyn S., Swensen, Stephen J., and Begg, Colin B.

Subjects
Lung cancer -- Diagnosis, Lung cancer -- Patient outcomes, CT imaging -- Usage, Cancer -- Diagnosis, Cancer -- Methods
Abstract

Studies were conducted to examine the impact of screening for lung cancer by computed tomography (CT) on lung cancer outcomes. Results revealed that screening for lung cancer with low-dose CT might increase the rate of lung cancer diagnosis and treatment by lung cancer resection, but might not significantly reduce the risk of advanced lung cancer or death from lung cancer.

Published
2007

33. Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer.

Author

Fox, Adam H., Jett, James R., Roy, Upal Basu, Johnson, Bruce E., King, Jennifer C., Martin, Nikki, Osarogiagbon, Raymond U., Rivera, M. Patricia, Rosenthal, Lauren S., Smith, Robert A., and Silvestri, Gerard A.

Subjects
*NON-small-cell lung carcinoma, *PULMONOLOGISTS, *NEEDLE biopsy, *BIOMARKERS
Abstract

Background: Targeted therapies for advanced non-small cell lung cancer (NSCLC) with oncogenic drivers have caused a paradigm shift in care. Biomarker testing is needed to assess eligibility for these therapies. Pulmonologists often perform bronchoscopy, providing tissue for both pathologic diagnosis and biomarker analysis. We performed this survey to define the existing knowledge and practices regarding the pulmonologists' role in biomarker testing for advanced NSCLC.Research Question: What is the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced NSCLC?Study Design and Methods: This cross-sectional study was performed using an electronic survey of a random sample of 7,238 pulmonologists. Questions focused on diagnostic steps and biomarker analyses for NSCLC.Results: A total of 453 pulmonologists responded. Respondents vary by reported lung cancer patient volume, ranging from 51% evaluating one to four new cases per month to 19% evaluating > 10 cases per month. Interventional training, academic practice setting, and higher volume of endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) were associated with increased knowledge of practice guidelines for the number of recommended passes during EBUS-TBNA (P < .05). Academic pulmonologists more commonly performed or referred for EBUS-TBNA than community pulmonologists (96% and 83%, respectively; P < .0005). Higher testing rates were associated with interventional training, academic setting, and the presence of an institutional policy, whereas lower testing rates were associated with general pulmonologists, practice in community settings, and lack of a guiding institutional policy (P < .05).Interpretation: Substantial differences among pulmonologists' evaluation of advanced NSCLC, variation in knowledge of available biomarkers and the importance of targeted therapies, and differences in institutional coordination likely lead to underutilization of biomarker testing. Interventional training appears to drive improved knowledge and practice for biomarker testing more than practice setting. Improvements are needed in tissue acquisition and interdisciplinary coordination to ensure universal and comprehensive testing for eligible patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

49. Superior pulmonary sulcus tumors and Pancoast's syndrome

Author

Arcasoy, Selim M. and Jett, James R.

Subjects
Lung tumors -- Care and treatment, Horner's syndrome -- Analysis
Abstract

The symptoms of Pancoast's syndrome are most often caused by a lung tumor, but as they are seen individually in many other diseases, correct diagnosis is frequently delayed. The syndrome includes shoulder and arm pain, Horner's syndrome indicated by a drooping eyelid and unequal pupils, and hand weakness. X-ray and computed tomography scans identify and localize the tumor while needle biopsy completes the diagnosis. Radiation and surgical resection of the tumor are the most common treatments, yielding a five-year survival rate of 20-35%.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results